Filtered By:
Cancer: Brain Cancers
Procedure: Transplants

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 66 results found since Jan 2013.

Exosomes Derived From Mesenchymal Stem Cells Pretreated With Ischemic Rat Heart Extracts Promote Angiogenesis via the Delivery of DMBT1
Cell Transplant. 2022 Jan-Dec;31:9636897221102898. doi: 10.1177/09636897221102898.ABSTRACTMesenchymal stem cell-derived exosomes (MSC-Exos) have been shown to promote angiogenesis. Treating MSCs with ischemic rat brain extracts was sufficient to augment their benefits in stroke. However, no similar analyses of ischemic heart extracts have been performed to date. We aim to determine whether MSC-Exos derived from MSCs pretreated with ischemic rat heart extract were able to promote angiogenesis and to clarify underlying mechanisms. ELISA (enzyme-linked immunosorbent assay) of heart extracts revealed a significant increase of ...
Source: Cell Transplantation - June 21, 2022 Category: Cytology Authors: Yi Xiao Ye Zhang Yuzhang Li Nanyin Peng Qin Liu Danyang Qiu Justin Cho Cesario V Borlongan Guolong Yu Source Type: research

Final Results of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells in Acute Ischemic Stroke (AMASCIS): A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Pilot Clinical Trial
We report the final trial results after 24 months of follow-up. Recruitment began in December 2014 and stopped in December 2017 after 19 of 20 planned patients were included. Six patients did not receive study treatment: two due to technical issues and four for acquiring exclusion criteria after randomization. The final study sample was composed of 13 patients (4 receiving AD-MSCs and 9 placebo). One patient in the placebo group died within the first week after study treatment delivery due to sepsis. Two non-treatment-related serious AEs occurred in the AD-MSC group and nine in the placebo group. The total number of AEs an...
Source: Cell Transplantation - March 18, 2022 Category: Cytology Authors: Elena de Celis-Ruiz Blanca Fuentes Mar ía Alonso de Leciñana Mar ía Gutiérrez-Fernández Alberto M Borobia Raquel Guti érrez-Zúñiga Gerardo Ruiz-Ares Laura Otero-Ortega Fernando Laso-Garc ía Mari Carmen G ómez-de Frutos Exuperio D íez-Tejedor Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Isolation and Purification of Self-Renewable Human Neural Stem Cells from iPSCs for Cell Therapy in Experimental Model of Ischemic Stroke
Methods Mol Biol. 2022;2389:165-175. doi: 10.1007/978-1-0716-1783-0_14.ABSTRACTNeural stem cell therapy has been galvanized by the discovery of pluripotent stem cells. The possibility to generate specialized central nervous system-specific differentiated cells using human somatic cells engineered to become induced pluripotent stem cells (iPSCs) was a game changer. This technology has broad applications in the field of regenerative medicine, in vitro disease modeling, targeted drug discovery, and precision medicine. Currently, iPSCs are one of the most promising cell sources amenable for commercialization and off-the-shelf ...
Source: Mol Biol Cell - September 24, 2021 Category: Molecular Biology Authors: Marcel M Daadi Source Type: research

Therapeutic oxygen delivery by perfluorocarbon-based colloids
Adv Colloid Interface Sci. 2021 May 1;294:102407. doi: 10.1016/j.cis.2021.102407. Online ahead of print.ABSTRACTAfter the protocol-related indecisive clinical trial of Oxygent, a perfluorooctylbromide/phospholipid nanoemulsion, in cardiac surgery, that often unduly assigned the observed untoward effects to the product, the development of perfluorocarbon (PFC)-based O2 nanoemulsions ("blood substitutes") has come to a low. Yet, significant further demonstrations of PFC O2-delivery efficacy have continuously been reported, such as relief of hypoxia after myocardial infarction or stroke; protection of vital organs during surg...
Source: Advances in Colloid and Interface Science - June 13, 2021 Category: Chemistry Authors: Marie Pierre Krafft Jean G Riess Source Type: research

Human neural stem cells improve early stage stroke outcome in delayed tissue plasminogen activator-treated aged stroke brains.
CONCLUSIONS: Aged stroke mice that received delayed tPA treatment in combination with hNSC transplantation exhibited reduced stroke pathophysiology in comparison to non-transplanted stroke mice with delayed tPA. This suggests that hNSC transplantation may synergize with already existing stroke therapies to benefit a larger stroke patient population. PMID: 32147438 [PubMed - as supplied by publisher]
Source: Experimental Neurology - March 4, 2020 Category: Neurology Authors: Boese A, Eckert A, Hamblin MH, Lee JP Tags: Exp Neurol Source Type: research

Factors affecting organ donation rate during devastating brain injuries: A 6-year data analysis.
Conclusions: Our findings showed that refusal by the family was the most common reason for failure of deceased organ donations. To maximize the number of procured organs, transplant communities need to focus on increasing awareness regarding brain death and organ donation and establish strategies to increase consent obtained from the families. PMID: 31903853 [PubMed - as supplied by publisher]
Source: Acta Chirurgica Belgica - January 8, 2020 Category: Surgery Tags: Acta Chir Belg Source Type: research

A Hallmark Clinical Study of Cord Blood Therapy in Adults with Ischemic Stroke.
Abstract The therapeutic application of human umbilical cord blood cells has been an area of great interest for at least the last 25 years. Currently, cord blood cells are approved for reconstitution of the bone marrow following myeloablation in both young and old patients with myeloid malignancies and other blood cancers. Translational studies investigating alternative uses of cord blood have also shown that these cells not only stimulate neurogenesis in the aged brain but are also potentially therapeutic in the treatment of adult neurodegenerative disorders including amyotrophic lateral sclerosis, Alzheimer's di...
Source: Cell Transplantation - June 10, 2019 Category: Cytology Authors: Sanberg PR, Ehrhart J Tags: Cell Transplant Source Type: research

Effects of Neurotrophic Factors in Glial Cells in the Central Nervous System: Expression and Properties in Neurodegeneration and Injury
Conclusion and Future Aspects This review summarizes available NTF expression data, compiles existing evidence on the effects of glial NTF signaling in healthy conditions and in disease models (Figure 1), and highlights the importance of this topic for future studies. The relationship between NTFs and glia is crucial for both the developing and adult brain. While some of these factors, such as NT-3 and CNTF, have highly potent effects on gliogenesis, others like BDNF and GDNF, are important for glia-mediated synapse formation. Neurotrophic factors play significant roles during neurodegenerative disorders. In many cases, ...
Source: Frontiers in Physiology - April 25, 2019 Category: Physiology Source Type: research